N/A N=52 Impact of Combined Behavioral Interventions on Cognitive Outcomes in MCI
Mild Cognitive Impairment
Primary: Rivermead Behavioral Memory Test — 11.08; 11.2; 12.31 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=25 Ketamine as an Adjunctive Therapy for Major Depression
Major Depressive Episode · Unipolar Depression · Bipolar Depression
Primary: The Hamilton Rating Scale for Depression-24 Item Version (HRSD-24) — 11.2; 16.6 score on a scale
Phase 1 N=16 Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment
Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of Lemborexant — 48.9; 46.6 nanogram per milliliter (ng/mL)
Phase 3 N=76 CORAL XT - Open-label Extension Trial of the CORAL Trial
Pain · Neoplasms · Chronic Pain
Primary: Number of Participants With Treatment Emergent Adverse Event (TEAEs) — 64 Participants
N/A N=40 Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy
Cow's Milk Allergy
Primary: Hypoallergenicity as Assessed by Reaction to Amino-acid Based Infant Formula — 0; 0; 0; 30 Participants
Phase 2 N=30 Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma
Ampulla of Vater Adenocarcinoma · Small Intestinal Adenocarcinoma · Stage III Ampulla of Vater Cancer AJCC v8
Primary: Number of Participants With Progression-free Survival (PFS) at Six Months — 68 percentage of participants
N/A N=419 Navigation From Community to Clinic to Promote CRC Screening in Underserved Populations
Colorectal Cancer
Primary: Primary Outcome is Clinic Attendance — 64; 17 Participants
N/A N=6 Exploratory Study of Circadian Relationships Between Social Behavior, Blood Pressure and Metabolomics
Healthy
Primary: Calls and Text Messages — 18.7; 0.9 Calls and text messages
N/A N=88 Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)
Cigarette Smoking
Primary: Change in Craving Score During Cue Exposure Task — -11.17; -8.84; -14.29 score on a scale — p=0.534
N/A N=23 A Family-based Primary Care Intervention to Enhance Older Men's Depression Care
Major Depression
Primary: Depressive Symptoms — 14.8; 15.3; 10.1; 13.0 units on a scale
N/A N=16 Running Retraining to Minimize Braking Forces
Athletic Injuries
Primary: Peak Braking Force — 0.24 Body Weight — p=0.001
Phase 2 N=67 Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer
Stomach Neoplasms · Esophageal Neoplasms
Primary: Number of Participants With an Objective Response — 25; 22 Participants
Phase 2 N=18 Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure
Allergic Asthma
Primary: Change From Baseline in Sputum Percent Neutrophils (%PMN) Following Ozone Exposure — 34.1; 36.5 percent neutrophils
Early Phase 1 N=8 Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
Pancreatic Adenocarcinoma · Recurrent Pancreatic Carcinoma · Stage III Pancreatic Cancer
Primary: Number of Participants With Adverse Events as Determined by CTCAE Version 4.03 — 1; 1; 4; 2 Participants
Phase 3 N=237 Dasotraline Pediatric Extension Study
Attention Deficit Hyperactivity Disorder
Primary: The Incidence of Overall Adverse Events, AEs , Serious Adverse Envents,(or SAEs), and AEs (or SAEs) Leading to Discontinuation — 144; 30; 3; 1 adverse events